Back to results
US 2022/0187299 A1Published application
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
AssigneeThe Regents of the University of California
InventorsLawrence Fong, Serena Kwek MacPhee, Jera Lewis
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of determining patient populations amenable or suitable for immunomodulatory treatment of disease such as cancer by measuring the relative or absolute levels of T-cell sub-populations correlated with disease such as cancer.
Claims17
-32. (canceled)
A method of determining whether cancer is amendable to treatment with an anti-CTLA-4 antibody product, the method comprising:
- (a) isolating a population of peripheral blood mononuclear cells (PBMCs) from a subject having cancer and a cancer-free subject;
- (b) quantifying the percentages of total CD4+ T cells expressing PD-1, PD-L1, and/or CTLA-4 in each of the populations;
- (c) comparing the percentages of total CD4+ T cells expressing PD-1, PD-L1, and/or CTLA-4 in the population of PBMCs from the subject having cancer and the percentages of total CD4+ T cells expressing PD-1, PD-L1, and/or CTLA-4 in the population of PBMCs from the cancer-free subject;
- and
- (d) determining the subject having cancer is amenable to treatment with an anti-CTLA-4 antibody product if:
- (1) the percentage of total CD4+ T cells expressing PD-1 in the population of PBMCs from the subject having cancer is lower than the percentage of total CD4+ T cells expressing PD-1 in the population of PBMCs from the cancer-free subject;
- or
- (2) the percentage of total CD4+ T cells expressing PD-L1 in the population of PBMCs from the subject having cancer is lower than the percentage of total CD4+ T cells expressing PD-L1 in the population of PBMCs from the cancer-free subject;
- or
- (3) the percentage of total CD4+ T cells expressing CTLA-4 in the population of PBMCs from the subject having cancer is higher than the percentage of total CD4+ T cells expressing CTLA-4 in the population of PBMCs from the cancer-free subject.
7 more elements
A method of determining whether cancer is amendable to treatment with an anti-CTLA-4 antibody product, the method comprising:
- (a) isolating a population of PBMCs from a subject having cancer and a cancer-free subject;
- (b) quantifying the percentages of CD4+ Teff cells expressing PD-1, PD-L1, and/or CTLA-4 in each of the populations;
- (c) comparing the percentages of CD4+ Teff cells expressing PD-1, PD-L1, and/or CTLA-4 in the population of PBMCs from the subject having cancer and the percentages of CD4+ Teff cells expressing PD-1, PD-L1, and/or CTLA-4 in the population of PBMCs from the cancer-free subject;
- and
- (d) diagnosing the subject having cancer is amenable to treatment with an anti-CTLA-4 antibody product if:
- (1) the percentage of CD4+ Teff cells expressing PD-1 in the population of PBMCs from the subject having cancer is lower than the percentage of CD4+ Teff cells expressing PD-1 in the population of PBMCs from the cancer-free subject;
- or
- (2) the percentage of CD4+ Teff cells expressing PD-L1 in the population of PBMCs from the subject having cancer is lower than the percentage of CD4+ Teff cells expressing PD-L1 in the population of PBMCs from the cancer-free subject;
- or
- (3) the percentage of CD4+ Teff cells expressing CTLA-4 in the population of PBMCs from the subject having cancer is higher than the percentage of CD4+ Teff cells expressing CTLA-4 in the population of PBMCs from the cancer-free subject.
7 more elements
A method of determining whether cancer is amendable to treatment with an anti-CTLA-4 antibody product, the method comprising:
- (a) isolating a population of PBMCs from a subject suspected of having cancer;
- (b) determining the percentages of CD4+ Teff cells expressing PD-1, PD-L1, and/or CTLA-4 the population of PBMCs;
- and
- (c) determining the subject's cancer is amendable to treatment with the anti-CTLA-4 antibody product if:
- the percentage of CD4+ Teff cells expressing PD-1 in the population of PBMCs from the subject having cancer is no greater than about 21%, or
- the percentage of CD4+ Teff cells expressing PD-L1 in the population of PBMCs from the subject having cancer is no greater than about 23.5%, or
- the percentage of CD4+ Teff cells expressing CTLA-4 in the population of PBMCs from the subject having cancer is at least about 15.6%;
- or
- determining the subject's cancer is not amenable to treatment with the anti-CTLA-4 antibody product if:
- the percentage of CD4+ Teff cells expressing PD-1 in the population of PBMCs from the subject having cancer is greater than about 21%, or
- the percentage of CD4+ Teff cells expressing PD-L1 in the population of PBMCs from the subject having cancer is greater than about 23.5%, or
- the percentage of CD4+ Teff cells expressing CTLA-4 in the population of PBMCs from the subject having cancer is less than about 15.6%.
9 more elements
Dependencies are inferred from the claim text.